Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Optimal Care Reported in Less Than Half of Adults With ASCVD

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

November 2023 News Roundup

News Opinion CV Team Dispatch

November 2023 News Roundup

November 01, 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

News Daily News

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

Michael O'Riordan

September 21, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.